ALBT: Avalon GloboCare Corp. Stock

by  •  • Comments Off on ALBT: Avalon GloboCare Corp. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 3.56
Enterprise Value ($M) 31.20
Book Value ($M) 5.40
Book Value / Share 4.94
Price / Book 0.66
NCAV ($M) -12.75
NCAV / Share -11.65
Price / NCAV -0.28

Profitability (mra)
Return on Invested Capital (ROIC) -1.04
Return on Assets (ROA) -0.72
Return on Equity (ROE) -2.00

Liquidity (mrq)
Quick Ratio 0.11
Current Ratio 0.11

Balance Sheet (mrq) ($M)
Current Assets 1.40
Assets 19.55
Liabilities 14.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 7,228 220,715 3.27
2025-01-13 2,351 18,416 12.77
2025-01-10 1,370 17,943 7.64

(click for more detail)

Similar Companies
AIMD – Ainos, Inc. AKAN – Akanda Corp.
AKBA – Akebia Therapeutics, Inc. ALDX – Aldeyra Therapeutics, Inc.
ALGS – Aligos Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io